Xu H - Search Results

1

Approaches of laparoscopic anatomical liver resection of segment 8 for hepatocellular carcinoma: a retrospective cohort study of short-term results at multiple centers in China.

Wang X, Li J, Cao J, Zhang Q, Wei Y, Cheng W, Liang X, Tian F, Wang X, Xu H, Chen J, Zhou N, Yang Z, Tao C, Wang H. Wang X, et al. Among authors: xu h. Int J Surg. 2023 Nov 1;109(11):3365-3374. doi: 10.1097/JS9.0000000000000608. Int J Surg. 2023. PMID: 37696250 Free PMC article.

2

Laparoscopic liver resection or enucleation for giant hepatic hemangioma: how to choose?

Zhang H, Xu H, Wen N, Li B, Chen K, Wei Y. Zhang H, et al. Among authors: xu h. Surg Endosc. 2024 Jun;38(6):3079-3087. doi: 10.1007/s00464-024-10820-z. Epub 2024 Apr 15. Surg Endosc. 2024. PMID: 38622227

3

Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis.

Xu H, Zhang H, Li B, Chen K, Wei Y. Xu H, et al. BMC Cancer. 2024 Aug 14;24(1):1008. doi: 10.1186/s12885-024-12772-y. BMC Cancer. 2024. PMID: 39143584 Free PMC article.

4

Impact of metabolic dysfunction-associated fatty liver disease on the outcomes following laparoscopic hepatectomy for hepatocellular carcinoma.

Xu H, Liu Y, Wei Y. Xu H, et al. Surg Endosc. 2024 Nov;38(11):6456-6463. doi: 10.1007/s00464-024-11239-2. Epub 2024 Sep 12. Surg Endosc. 2024. PMID: 39266759

5

Short- and long-term outcomes following laparoscopic liver resection for hepatocellular carcinoma combined with type I/II portal vein tumor thrombus.

Zhang H, Xu H, Wen N, Li B, Chen K, Wei Y. Zhang H, et al. Among authors: xu h. Updates Surg. 2025 Jan 13. doi: 10.1007/s13304-025-02065-9. Online ahead of print. Updates Surg. 2025. PMID: 39806238

6

Peroxidase-Mimetic Iron Silicate Nanosheets Coordinated with Indocyanine Green for Enhanced Anti-Tumor Therapy.

Zhu S, Xu H, Guo W, Yang M, Tan H, Hou S, Yao J, Luo H, Yao Y, Zhao J, Wei Y, Sun X, Ying B. Zhu S, et al. Among authors: xu h. Adv Healthc Mater. 2024 Dec;13(32):e2403002. doi: 10.1002/adhm.202403002. Epub 2024 Sep 25. Adv Healthc Mater. 2024. PMID: 39319489

7

Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models.

Lu X, Deng S, Xu J, Green BL, Zhang H, Cui G, Zhou Y, Zhang Y, Xu H, Zhang F, Mao R, Zhong S, Cramer T, Evert M, Calvisi DF, He Y, Liu C, Chen X. Lu X, et al. Among authors: xu h, xu j. J Clin Invest. 2023 Jun 1;133(11):e163291. doi: 10.1172/JCI163291. J Clin Invest. 2023. PMID: 37040183 Free PMC article.

8

Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis.

Zhou Y, Cui G, Xu H, Chun J, Yang D, Zhang Z, Yang L, Wang J, Wan M, Calvisi DF, Lin S, Chen X, Wang H. Zhou Y, et al. Among authors: xu h. Cell Death Dis. 2023 Jul 27;14(7):476. doi: 10.1038/s41419-023-05958-y. Cell Death Dis. 2023. PMID: 37500626 Free PMC article.

9

TSC/mTORC1 mediates mTORC2/AKT1 signaling in c-MYC-induced murine hepatocarcinogenesis via centromere protein M.

Zhou Y, Zhang S, Qiu G, Wang X, Yonemura A, Xu H, Cui G, Deng S, Chun J, Chen N, Xu M, Song X, Wang J, Xu Z, Deng Y, Evert M, Calvisi DF, Lin S, Wang H, Chen X. Zhou Y, et al. Among authors: xu m, xu h, xu z. J Clin Invest. 2024 Sep 26;134(22):e174415. doi: 10.1172/JCI174415. J Clin Invest. 2024. PMID: 39325536 Free PMC article.

10

Noninvasive assessment of liver fibrosis in mini pigs using an ¹⁸F-AlF-NOTA-RGD2 PET/CT molecular probe.

Liu W, Xu H, Zhang H, Xie M, Liu Y, Wang L, Wu X, Feng Y, Chen K. Liu W, et al. Among authors: xu h. Heliyon. 2024 Jul 31;10(15):e35502. doi: 10.1016/j.heliyon.2024.e35502. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39170113 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45,801 results

Search Page

Filters